| abstract |
Provided is an antigen-binding polypeptide specifically binding to B7H3. The antigen-binding polypeptide contains at least one complementarity determining region (CDR) of an antibody heavy chain variable region (VH), wherein the VH contains the amino acid sequence represented by SEQ ID NO:25. Also provided are a chimeric antigen receptor containing the antigen-binding polypeptide, and a universal CAR-T cell containing the chimeric antigen receptor. TCR and HLA-A genes expressed by the cell are knocked out while a tumor cell surface antigen is recognized, thereby reducing the immune rejection caused by allogeneic CAR-T therapy, prolonging the cell survival time, and improving an anti-tumor effect. |